Summit Lung Cancer Drug Falls Short on Key Survival Goal in Global Study, Putting FDA Approval in Doubt

Despite achieving statistically signficant improvement in progression-free survival in North American and European patients, Summit’s drug ivonescimab fell short of the other Phase 3 goal measuring overall survival. It’s the first Phase 3 readout for an emerging class of bispecific antibodies that treat cancer by blocking two targets, PD-1 and VEGF. The post Summit Lung…

Read More

Cuando deje este mundo, que sea de forma ecológica

Cada año, durante nuestras vacaciones familiares en Cape Cod, disfrutamos de todos los placeres clásicos del verano: escalar dunas, caminar por la playa, observar focas, comer ostras y leer los libros que nos habíamos propuesto durante todo el año. También hacer compras. Mi nieto quería unos juguetes pequeños. Mi hija aprovechó para llevarse varios rompecabezas…

Read More

SOAR Act Would Help Individuals Relying on Oxygen Thrive

The bill clarifies very specific patient protections and codifies a Patient’s Bill of Rights, all of which would ensure that individuals receiving supplemental oxygen in the home – and their suppliers – understand requirements around equipment, communications, and care options.  The post SOAR Act Would Help Individuals Relying on Oxygen Thrive appeared first on MedCity…

Read More